{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:15:10Z","timestamp":1793459710693,"version":"4.5.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>We performed a systematic review and meta-analysis of the cognitive effectiveness and safety of lecanemab on subjects with Alzheimer's disease (AD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We screened the literature published before February 2023 in PubMed, Embase, Web of Science, and Cochrane that were searched for randomized controlled trials testing lecanemab for the treatment of cognitive decline in patients with MCI or AD. Outcomes measured were CDR Sum of Boxes (CDR-SB), Alzheimer's Disease Composite Score (ADCOMS), AD Assessment Scale\u2013Cognitive Subscale (ADAS-Cog), Clinical Dementia Rating (CDR), amyloid PET Standardized Uptake Volume Ratio (SUVr), amyloid burden on PET, and risks for adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of four randomized controlled trials were included, involving 3,108 AD patients (1,695 lecanemab groups and 1,413 placebo groups) to synthesize evidence. Baseline characteristics of the two groups were similar in all outcomes except that ApoE 4 status and higher MMSE score were observed in the lecanemab group. It is reported that lecanemab was beneficial to stabilize or slow down the decrease in CDR-SB (WMD: \u22120.45; 95% CI: \u22120.64, \u22120.25;<jats:italic>p<\/jats:italic>&amp;lt; 0.00001), ADCOMS (WMD: \u22120.05; 95% CI: \u22120.07, \u22120.03;<jats:italic>p<\/jats:italic>&amp;lt; 0.00001), ADAS-cog (WMD: \u22121.11; 95% CI: \u22121.64, \u22120.57;<jats:italic>p<\/jats:italic>&amp;lt; 0.0001), amyloid PET SUVr (WMD: \u22120.15; 95% CI: \u22120.48, 0.19;<jats:italic>p<\/jats:italic>= 0.38), amyloid burden on PET (WMD:\u221235.44; 95% CI: \u221265.22,\u22125.67;<jats:italic>p<\/jats:italic>= 0.02), adverse events (subjects with any TEAE) (OR: 0.73; 95% CI: 0.25, 2.15;<jats:italic>p<\/jats:italic>= 0.57), ARIA-E (OR:8.95; 95% CI: 5.36, 14.95;<jats:italic>p<\/jats:italic>&amp;lt; 0.00001), and ARIA-H (OR:2.00; 95% CI: 1.53, 2.62;<jats:italic>p<\/jats:italic>&amp;lt; 0.00001) in early AD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our analysis found that lecanemab showed significant positive statistical efficacy with respect to cognition, function, and behavior in patients with early AD though the actual clinical significance is yet to be established<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/#recordDetails<\/jats:ext-link>, identifier: CRD42023393393.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnagi.2023.1169499","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T05:54:09Z","timestamp":1683266049000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":69,"title":["Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials"],"prefix":"10.3389","volume":"15","author":[{"given":"Yue","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuewei","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/alz.12638","article-title":"2022 Alzheimer's disease facts and figures","volume":"18","year":"2022","journal-title":"Alzheimers. Dement"},{"key":"B2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12883-017-0850-1","article-title":"Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials","volume":"17","author":"Abushouk","year":"2017","journal-title":"BMC Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3389\/fnins.2014.00327","article-title":"A review of \u03b2-amyloid neuroimaging in Alzheimer's disease","volume":"8","author":"Adlard","year":"2014","journal-title":"Front. Neurosci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3233\/JAD-230040","article-title":"Russian roulette with alzheimer's disease patients: do the cognitive benefits of lecanemab outweigh the risk of edema and stroke?","volume":"92","author":"Atwood","year":"2023","journal-title":"J. Alzheimers Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12944-015-0145-8","article-title":"Comparative chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from Polygonum hydropiper L: a preliminary anti- Alzheimer's study","volume":"14","author":"Ayaz","year":"2015","journal-title":"Lipids Health Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2967\/jnumed.123.265667","article-title":"Amyloid imaging-based food and drug administration approval of lecanemab to treat alzheimer disease-what lasts long finally becomes good?","volume":"64","author":"Barthel","year":"2023","journal-title":"J. Nucl. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00259-020-05187-x","article-title":"Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives","volume":"48","author":"Cotta Ramusino","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3233\/JAD-180766","article-title":"Treatment combinations for Alzheimer's disease: current and future pharmacotherapy options","volume":"67","author":"Cummings","year":"2019","journal-title":"J. Alzheimers. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"key":"B12","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1471-4159.2007.04759.x","article-title":"Sensitive ELISA detection of amyloid-beta protofibrils in biological samples","volume":"103","author":"Englund","year":"2007","journal-title":"J. Neurochem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrneurol.2009.175","article-title":"Changing perspectives regarding late-life dementia","volume":"5","author":"Fotuhi","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fnagi.2018.00224","article-title":"Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer's disease?","volume":"10","author":"Fulop","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40035-020-00214-1","article-title":"SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-beta antibody in a mouse model of Alzheimer's disease","volume":"9","author":"Gustavsson","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"B16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's Disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Methodol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","article-title":"NLRP3 inflammasome activation drives tau pathology","volume":"575","author":"Ising","year":"2019","journal-title":"Nature."},{"key":"B21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/JAD-220046","article-title":"Safety and efficacy of monoclonal antibodies for Alzheimer's disease: a systematic review and meta-analysis of published and unpublished clinical trials","volume":"87","author":"Lacorte","year":"2022","journal-title":"J. Alzheimer's Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1177\/0962280220910172","article-title":"Hybrid test for publication bias in meta-analysis","volume":"29","author":"Lin","year":"2020","journal-title":"Stat. Methods Med. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401 - A clinical study in Alzheimer's disease with a protofibril selective A\u03b2 antibody","author":"Logovinsky","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell."},{"key":"B26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.nbd.2009.08.007","article-title":"An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease","volume":"36","author":"Lord","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/jnnp-2020-323497","article-title":"Anti-A\u03b2 agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis","volume":"91","author":"Lu","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"B28","first-page":"S145","article-title":"BAN2401 in early Alzheimer's disease: a placebo-controlled, double-blind, parallel-group, 18-month study with an open-label extension phase to confirm safety and efficacy (clarity AD)","volume":"6","author":"Lynch","year":"2019","journal-title":"J. Prevent. Alzheimer's Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"Mcdade","year":"2022","journal-title":"Alzheimer's Res. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The clinical dementia rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/archneurol.2009.269","article-title":"Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease","volume":"66","author":"Morris","year":"2009","journal-title":"Arch. Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"23515","DOI":"10.1074\/jbc.R115.677211","article-title":"Amyloid precursor protein (APP) metabolites APP intracellular fragment (AICD), A\u03b242, and tau in nuclear roles","volume":"290","author":"Multhaup","year":"2015","journal-title":"J. Biol. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaneurol.2017.2188","article-title":"Apolipoprotein E genotype and sex risk factors for alzheimer disease: a meta-analysis","volume":"74","author":"Neu","year":"2017","journal-title":"JAMA Neurol."},{"key":"B34","first-page":"E170","article-title":"The A\u03b2 protofibril selective antibody mAb158 prevents accumulation of A\u03b2 in astrocytes and rescues neurons from A\u03b2 induced apoptosis","volume":"65","author":"Nikitidou","year":"2017","journal-title":"GLIA"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","article-title":"Staging dementia using clinical dementia rating scale sum of boxes scores: a Texas alzheimer's research consortium study","volume":"65","author":"O'Bryant","year":"2008","journal-title":"Arch. Neurol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/v7gm2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"B37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nature Reviews Neurology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1093\/brain\/awab163","article-title":"Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032014","article-title":"Large aggregates are the major soluble A\u03b2 species in AD brain fractionated with density gradient ultracentrifugation","author":"Sehlin","year":"2012","journal-title":"PLoS ONE."},{"key":"B40","doi-asserted-by":"publisher","first-page":"10759","DOI":"10.1038\/ncomms10759","article-title":"Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease","volume":"7","author":"Sehlin","year":"2016","journal-title":"Nat. Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nature medicine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12974-018-1134-4","article-title":"The A beta protofibril selective antibody mAb158 prevents accumulation of A beta in astrocytes and rescues neurons from A beta-induced cell death","volume":"15","author":"Sollvander","year":"2018","journal-title":"J. Neuroinflammation."},{"key":"B44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers. Res. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/alz.057773","article-title":"PRX012 induces microglia-mediated clearance of pyroglutamate-modified A\u03b2 in Alzheimer's Disease brain tissue","volume":"17","author":"Tam","year":"2021","journal-title":"Alzheimer's and Dementia."},{"key":"B46","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jalz.2016.01.002","article-title":"Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials","volume":"12","author":"Thomas","year":"2016","journal-title":"Alzheimers. Dement."},{"key":"B47","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.2147\/IJN.S200490","article-title":"Alzheimer's disease: pathogenesis, diagnostics, and therapeutics","volume":"14","author":"Tiwari","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1161\/CIRCRESAHA.118.313563","article-title":"Getting to the Heart of Alzheimer Disease","volume":"124","author":"Tublin","year":"2019","journal-title":"Circ. Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00702-019-01975-4","article-title":"Dementia spectrum disorders: lessons learnt from decades with PET research","volume":"126","author":"Wilson","year":"2019","journal-title":"J. Neural. Transm. (Vienna)."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2023.1169499\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T04:00:50Z","timestamp":1702353650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2023.1169499\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":51,"alternative-id":["10.3389\/fnagi.2023.1169499"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2023.1169499","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"article-number":"1169499"}}